Risk of symptom recurrence with medication discontinuation in first-episode psychosis: A systematic review

Schizophrenia Research

Volumn 152, Issue 2-3, 2014, Pages 408-414

  Zipursky, Robert B ^a   Menezes, Natasja M ^a   Streiner, David L ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antipsychotic; Discontinuation; First episode psychosis; Recurrence; Relapse; Schizophrenia; Withdrawal

Indexed keywords

NEUROLEPTIC AGENT;

DRUG WITHDRAWAL; FOLLOW UP; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOSIS; RECURRENCE RISK; REMISSION; REVIEW; RISK ASSESSMENT; SYMPTOM ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT WITHDRAWAL;

ANTIPSYCHOTIC; DISCONTINUATION; FIRST EPISODE PSYCHOSIS; RECURRENCE; RELAPSE; SCHIZOPHRENIA; WITHDRAWAL;

ANTIPSYCHOTIC AGENTS; HUMANS; PSYCHOTIC DISORDERS; RECURRENCE;

EID: 84892865012     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.08.001     Document Type: Review

References (53)

1. Allison D.B., Newcomer J.W., Dunn A.L., Blumenthal J.A., Fabricatore A.N., Daumit G.L., Cope M.B., Riley W.T., Vreeland B., Hibbeln J.R., Alpert J.E. Obesity among those with mental disorders: a National Institute of Mental Health meeting report. Am. J. Prev. Med. 2009, 36(4):341-350.
2. Amore M., Menchetti M., Tonti C., Scarlatti F., Lundgren E., Esposito W., Berardi D. Predictors of violent behavior among acute psychiatric patients: clinical study. Psychiatry Clin. Neurosci. 2008, 62(3):247-255.
3. Boonstra G., Burger H., Grobbee D.E., Kahn R.S. Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenia patients: results from an aborted randomised trial. Int. J. Psychiatry Clin. Pract. 2011, 15(2):128-134.
4. Bromet E.J., Kotov R., Fochtmann L.J., Carlson G.A., Tanenberg-Karant M., Ruggero C., Chang S.W. Diagnostic shifts during the decade following first admission for psychosis. Am. J. Psychiatry 2011, 168(11):1186-1194.
5. Canadian Psychiatric Association Canadian clinical practice guidelines for the treatment of schizophrenia. Can. J. Psychiatry 1998, 43(Suppl. 2):25S-40S.
6. Chen E.Y., Hui C.L., Lam M.M., Chiu C.P., Law C.W., Chung D.W., Tso S., Pang E.P., Chan K.T., Wong Y.C., Mo F.Y., Chan K.P., Yao T.J., Hung S.F., Honer W.G. Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. BMJ 2010, 341:c4024.
7. Correll C.U., Leucht S., Kane J.M. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am. J. Psychiatry 2004, 161(3):414-425.
8. Crespo-Facorro B., Perez-Iglesias R., Mata I., Caseiro O., Martinez-Garcia O., Pardo G., Ramirez-Bonilla M., Pelayo-Teran J.M., Vazquez-Barquero J.L. Relapse prevention and remission attainment in first-episode non-affective psychosis. A randomized, controlled 1-year follow-up comparison of haloperidol, risperidone and olanzapine. J. Psychiatr. Res. 2011, 45(6):763-769.
9. Crow T.J., MacMillan J.F., Johnson A.L., Johnstone E.C. A randomised controlled trial of prophylactic neuroleptic treatment. Br. J. Psychiatry 1986, 148:120-127.
10. Emsley R., Oosthuizen P., Koen L., Niehaus D.J., Medori R., Rabinowitz J. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Clin. Ther. 2008, 30(12):2378-2386.
11. Emsley R., Oosthuizen P.P., Koen L., Niehaus D.J., Martinez G. Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2years: a 3-year open-label clinical study. J. Clin. Psychiatry 2012, 73(4):e541-e547.
12. Endicott J., Spitzer R.L., Fleiss J.L., Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch. Gen. Psychiatry 1976, 33(6):766-771.
13. Gaebel W., Janner M., Frommann N., Pietzcker A., Kopcke W., Linden M., Muller P., Muller-Spahn F., Tegeler J. First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophr. Res. 2002, 53(1-2):145-159.
14. Gaebel W., Riesbeck M., Wolwer W., Klimke A., Eickhoff M., von Wilmsdorff M., Jockers-Scherubl M.C., Kuhn K.U., Lemke M., Bechdolf A., Bender S., Degner D., Schlosser R., Schmidt L.G., Schmitt A., Jager M., Buchkremer G., Falkai P., Klingberg S., Kopcke W., Maier W., Hafner H., Ohmann C., Salize H.J., Schneider F., Moller H.J. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J. Clin. Psychiatry 2007, 68(11):1763-1774.
15. Gaebel W., Riesbeck M., Wolwer W., Klimke A., Eickhoff M., von Wilmsdorff M., Lemke M., Heuser I., Maier W., Huff W., Schmitt A., Sauer H., Riedel M., Klingberg S., Kopcke W., Ohmann C., Moller H.J. Relapse prevention in first-episode schizophrenia-maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. J. Clin. Psychiatry 2011, 72(2):205-218.
16. Gardos G. Are antipsychotic drugs interchangeable?. J. Nerv. Ment. Dis. 1974, 159(5):343-348.
17. Gilbert P.L., Harris M.J., McAdams L.A., Jeste D.V. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch. Gen. Psychiatry 1995, 52(3):173-188.
18. Girgis R.R., Phillips M.R., Li X., Li K., Jiang H., Wu C., Duan N., Niu Y., Lieberman J.A. Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. Br. J. Psychiatry 2011, 199(4):281-288.
19. Gitlin M., Nuechterlein K., Subotnik K.L., Ventura J., Mintz J., Fogelson D.L., Bartzokis G., Aravagiri M. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am. J. Psychiatry 2001, 158(11):1835-1842.
20. Gleeson J.F., Cotton S.M., Alvarez-Jimenez M., Wade D., Gee D., Crisp K., Pearce T., Newman B., Spiliotacopoulos D., Castle D., McGorry P.D. A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients. J. Clin. Psychiatry 2009, 70(4):477-486.
21. Guy W. Clinical global impressions, ECDEU assessment manual for psychopharmacology 1976, 218-220.
22. Harrow M., Jobe T.H., Faull R.N. Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study. Psychol. Med. 2012, 42(10):2145-2155.
23. Herz M.I., Glazer W.M., Mostert M.A., Sheard M.A., Szymanski H.V., Hafez H., Mirza M., Vana J. Intermittent vs maintenance medication in schizophrenia. Two-year results. Arch. Gen. Psychiatry 1991, 48((4):333-339.
24. Hogarty G.E., Ulrich R.F. The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. J. Psychiatr. Res. 1998, 32(3-4):243-250.
25. Hor K., Taylor M. Suicide and schizophrenia: a systematic review of rates and risk factors. J. Psychopharmacol. 2010, 24(4):81-90. (Suppl.).
26. Jablensky A., Hugler H., Von Cranach M., Kalinov K. Kraepelin revisited: a reassessment and statistical analysis of dementia praecox and manic-depressive insanity in 1908. Psychol. Med. 1993, 23(4):843-858.
27. Jackson H.J., McGorry P.D. The Recognition and Management of Early Psychosis: A Preventive Approach 2009, Cambridge University Press, Cambridge, UK; New York. 2nd ed.
28. Jolley A.G., Hirsch S.R., Morrison E., McRink A., Wilson L. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ 1990, 301(6756):837-842.
29. Kane J.M., Rifkin A., Quitkin F., Nayak D., Ramos-Lorenzi J. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Arch. Gen. Psychiatry 1982, 39(1):70-73.
30. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
31. Lambert M., Naber D., Schacht A., Wagner T., Hundemer H.P., Karow A., Huber C.G., Suarez D., Haro J.M., Novick D., Dittmann R.W., Schimmelmann B.G. Rates and predictors of remission and recovery during 3years in 392 never-treated patients with schizophrenia. Acta Psychiatr. Scand. 2008, 118(3):220-229.
32. Lehman A.F., Lieberman J.A., Dixon L.B., McGlashan T.H., Miller A.L., Perkins D.O., Kreyenbuhl J. Practice guideline for the treatment of patients with schizophrenia, second edition. Am. J. Psychiatry 2004, 161(2):1-56. (Suppl.).
33. Leucht S., Tardy M., Komossa K., Heres S., Kissling W., Salanti G., Davis J.M. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012, 379(9831):2063-2071.
34. Lieberman J.A. Prediction of outcome in first-episode schizophrenia. J. Clin. Psychiatry 1993, 54:13-17. (Suppl.).
35. Lieberman J., Jody D., Geisler S., Alvir J., Loebel A., Szymanski S., Woerner M., Borenstein M. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch. Gen. Psychiatry 1993, 50(5):369-376.
36. Llorca P.M. Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Res. 2008, 161(2):235-247.
37. Malla A., Norman R., Bechard-Evans L., Schmitz N., Manchanda R., Cassidy C. Factors influencing relapse during a 2-year follow-up of first-episode psychosis in a specialized early intervention service. Psychol. Med. 2008, 38(11):1585-1593.
38. Masand P.S., Roca M., Turner M.S., Kane J.M. Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. Prim. Care Companion J. Clin. Psychiatry 2009, 11(4):147-154.
39. McCreadie R.G., Wiles D., Grant S., Crockett G.T., Mahmood Z., Livingston M.G., Watt J.A., Greene J.G., Kershaw P.W., Todd N.A., et al. The Scottish first episode schizophrenia study. VII. Two-year follow-up. Scottish Schizophrenia Research Group. Acta Psychiatr. Scand. 1989, 80(6):597-602.
40. Menezes N.M., Arenovich T., Zipursky R.B. A systematic review of longitudinal outcome studies of first-episode psychosis. Psychol. Med. 2006, 36(10):1349-1362.
41. Overall J., Gorham D. The Brief Psychiatric Rating Scale. Psychol. Rep. 1962, 10(3):799-812.
42. Rabiner C.J., Wegner J.T., Kane J.M. Outcome study of first-episode psychosis. I: Relapse rates after 1year. Am. J. Psychiatry 1986, 143(9):1155-1158.
43. Ram R., Bromet E.J., Eaton W.W., Pato C., Schwartz J.E. The natural course of schizophrenia: a review of first-admission studies. Schizophr. Bull. 1992, 18(2):185-207.
44. Rifkin A., Quitkin F., Klein D.F. Fluphenazine decanoate, oral fluphenazine, and placebo in treatment of remitted schizophrenics. II. Rating scale data. Arch. Gen. Psychiatry 1977, 34(10):1215-1219.
45. Robinson D., Woerner M.G., Alvir J.M., Bilder R., Goldman R., Geisler S., Koreen A., Sheitman B., Chakos M., Mayerhoff D., Lieberman J.A. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch. Gen. Psychiatry 1999, 56(3):241-247.
46. Spitzer R.L., Endicott J., Robins E. Research diagnostic criteria: rationale and reliability. Arch. Gen. Psychiatry 1978, 35(6):773-782.
47. Takeuchi H., Suzuki T., Uchida H., Watanabe K., Mimura M. Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms. Schizophr. Res. 2012, 134(2-3):219-225.
48. Viguera A.C., Baldessarini R.J., Hegarty J.D., van Kammen D.P., Tohen M. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch. Gen. Psychiatry 1997, 54(1):49-55.
49. Wiersma D., Nienhuis F.J., Slooff C.J., Giel R. Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizophr. Bull. 1998, 24(1):75-85.
50. Wistedt B., Jorgensen A., Wiles D. A depot neuroleptic withdrawal study. Plasma concentration of fluphenazine and flupenthixol and relapse frequency. Psychopharmacology (Berl) 1982, 78(4):301-304.
51. Wunderink L., Nienhuis F.J., Sytema S., Slooff C.J., Knegtering R., Wiersma D. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J. Clin. Psychiatry 2007, 68(5):654-661.
52. Zipursky R.B., Schulz S.C. The Early Stages of Schizophrenia 2001, American Psychiatric Pub, Washington, DC. 1st ed.
53. Zipursky R.B., Reilly T.J., Murray R.M. The myth of schizophrenia as a progressive brain disease. Schizophr. Bull. 2013, (Epub ahead of print, Dec 7, in press).